All Comments by Stefan Lichtenthaler

  1. BACE1 Conditional Knockouts Model Adult BACE Inhibition
  2. Merck Axes Verubecestat for Prodromal AD, Researchers Say ‘Go Earlier’
  3. More Support for Amyloid Hypothesis: Protective APP Mutation Lowers Aβ in Blood
  4. Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
  5. New MO for Purported Anti-Amyloid Drug: Shielding APP from BACE?
  6. Paper Alert: Verubecestat Preclinical and Phase 1 Data Published
  7. Partners in Crime: APP Fragment and Endosomal Protein Impair Endocytosis
  8. Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
  9. β-Secretase BACE1 regulates hippocampal and reconstituted M-currents in a β-subunit-like fashion.
  10. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions.
  11. Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes.
  12. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles.
  13. Lilly Halts Phase 2 Trial of BACE Inhibitor Due to Liver Toxicity
  14. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment.
  15. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments.